



Medicine Supply Notification

MSN/2023/089

Somatropin (Genotropin® MiniQuick) 1.4mg powder and solvent for solution for injection pre-filled disposable devices

Somatropin (Genotropin® MiniQuick) 1.6mg powder and solvent for solution for injection pre-filled disposable devices

Somatropin (Genotropin® MiniQuick) 1.8mg powder and solvent for solution for injection pre-filled disposable devices

Tier 2 – medium impact*

Date of issue: 21/09/2023

Link: [Medicines Supply Tool](#)

Summary

- Somatropin (Genotropin® MiniQuick) 1.4mg, 1.6mg and 1.8mg powder and solvent for solution for injection pre-filled disposable (single dose) devices will be in limited supply until w/c 1st January 2024.
- The following somatropin preparations remain available and will be able to support increased demand:
 - Somatropin (Genotropin® GoQuick) 12mg powder and solvent for solution for injection pre-filled, multi-dose pens
 - Somatropin (Genotropin®) 12mg powder and solvent for solution for injection multi-dose cartridges
 - Somatropin (Genotropin® MiniQuick) 1.2mg and 2mg powder and solvent for solution for injection pre-filled disposable (single dose) devices

Actions Required

Secondary care pharmacy teams should work with clinical specialists and their local pharmacy homecare leads to:

- ensure that new patients are not initiated on Genotropin® MiniQuick 1.4mg, 1.6mg and 1.8mg devices until resupply;
- review all patients, including those under shared care arrangements, prescribed Genotropin® MiniQuick 1.4mg, 1.6mg and 1.8mg devices, and determine:
 - which patients need to remain on these devices (e.g. visual impairment or have no refrigerator). Remaining stock of Genotropin® MiniQuick 1.4mg, 1.6mg and 1.8mg devices is to be reserved for patients who cannot be switched. Please note, to obtain remaining stock contact Pfizer Customer Service Team: 0800 0327907
 - issue a new prescription for:
 - Genotropin® 12mg cartridges (0.2mg dose increments) to be used with a re-usable injection device (Genotropin Pen) to deliver doses of 1.4mg, 1.6mg or 1.8mg in patients able to manage the change in device; or

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- Genotropin® GoQuick 12mg reusable multi-dose pens (delivers dose increments of 0.15mg) for patients on 1.8mg dose who are able to use the pen;
 - Genotropin® MiniQuick 1.2mg or 2mg device for those patients still being dose titrated and being considered for a change to these doses delivered by the MiniQuick device.
- ensure that patients switched from the single use MiniQuick injection devices to Genotropin® 12mg cartridges and Genotropin® GoQuick 12mg pens are aware these are multi-dose devices and need to be stored in a refrigerator;
 - ensure all new prescriptions are sent to their current homecare service provider or outpatient dispensary; and
 - communicate with home care providers if nurse led injection training is required on use of new device.

Homecare providers should:

- ensure that once a new prescription for Genotropin® 12mg cartridges, Genotropin® GoQuick 12mg pens or Genotropin® MiniQuick 1.2mg or 2mg device is received, the patient's existing Genotropin® MiniQuick 1.4mg, 1.6mg or 1.8mg device prescription is immediately cancelled;
- call patients to inform them of the change to their prescription while arranging delivery and offer nursing support on how to use the new device; and
- work with the prescriber and the Trust homecare lead to ensure nurse led training or, if available, administration support is offered where requested.

Outpatient dispensaries should ensure that:

- once a new prescription for Genotropin® 12mg cartridges, Genotropin® GoQuick 12mg pens or Genotropin® MiniQuick 1.2mg or 2mg device is received, the patient's existing Genotropin® MiniQuick 1.4mg, 1.6mg or 1.8mg device prescription is cancelled;
- patients receive a patient education pack and are counselled about the change in prescription at the point of first dispensing; and
- patients are directed back to their specialist team if they highlight a need for additional nurse-led training or ongoing nursing support.

GP surgeries who prescribe Genotropin® MiniQuick 1.4mg, 1.6mg and 1.8mg devices should:

- proactively identify all patients on these products and refer them to their specialist for review and a switch to an appropriate alternative as above.

Supporting information

[See links for further information](#)

- [SmPC Genotropin® MiniQuick](#)
- [SmPC Genotropin® 12mg powder and solvent](#)
- [BNF Somatropin](#)

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Regional Pharmacy Procurement Specialist, who will escalate to national teams if required.

REGION	Full Name	Email
Midlands	Andi Swain (East Midlands)	andi.swain@nhs.net
	Diptyka Hart (West Midlands)	Diptyka.Hart@uhb.nhs.uk

East of England	James Kent	james.kent@nhs.net
London	Jackie Eastwood	jacqueline.eastwood@gstt.nhs.uk
North East and Yorkshire	David Allwood (Yorkshire)	davidallwood@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2023/089.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.